Life
Briefing: Vertex says its drug successfully reduced marker of kidney disease in late-stage trial
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
editorial-staff
1 min read
Updated about 1 month ago
Summary
- Summary pending editorial review.
Key Facts
| Fact | Value |
|---|---|
| Drug Acquisition Cost | $4.9 billion |
| Disease Targeted | IgA nephropathy |
| Marker Reduction | 50% |